Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $6,603 | $7,384 | $7,085 | $5,214 |
| % Growth | -10.6% | 4.2% | 35.9% | – |
| Cost of Goods Sold | $4,361 | $4,536 | $4,277 | $2,943 |
| Gross Profit | $2,242 | $2,849 | $2,808 | $2,271 |
| % Margin | 34% | 38.6% | 39.6% | 43.6% |
| R&D Expenses | $238 | $262 | $235 | $212 |
| G&A Expenses | $301 | $260 | $256 | $244 |
| SG&A Expenses | $349 | $307 | $406 | $373 |
| Sales & Mktg Exp. | $49 | $47 | $150 | $129 |
| Other Operating Expenses | $990 | -$210 | $357 | $308 |
| Operating Expenses | $1,578 | $358 | $998 | $893 |
| Operating Income | $664 | $2,487 | $2,582 | $1,919 |
| % Margin | 10.1% | 33.7% | 36.4% | 36.8% |
| Other Income/Exp. Net | $0 | $2 | $3 | $1,766 |
| Pre-Tax Income | $664 | $2,489 | $2,585 | $3,685 |
| Tax Expense | $217 | $339 | $314 | $293 |
| Net Income | $405 | $2,025 | $2,007 | $2,874 |
| % Margin | 6.1% | 27.4% | 28.3% | 55.1% |
| EPS | 0.47 | 2.34 | 2.32 | 3.31 |
| % Growth | -79.9% | 0.9% | -29.9% | – |
| EPS Diluted | 0.47 | 2.34 | 2.32 | 3.3 |
| Weighted Avg Shares Out | 862 | 865 | 865 | 868 |
| Weighted Avg Shares Out Dil | 862 | 865 | 865 | 871 |
| Supplemental Information | – | – | – | – |
| Interest Income | $90 | $230 | $227 | $256 |
| Interest Expense | $141 | $124 | $83 | $25 |
| Depreciation & Amortization | $324 | $339 | $285 | $197 |
| EBITDA | $1,130 | $2,847 | $2,953 | $3,895 |
| % Margin | 17.1% | 38.5% | 41.7% | 74.7% |